Cardiovascular disease and mental illness commonly co-occur. Addressing them together can improve both mental health and ...

The guideline recommendations advise universal use of hydroxychloroquine, minimizing steroids, and earlier introduction of ...

Shares of Biogen Inc. BIIB advanced 2.12% to $133.13 Friday, on what proved to be an all-around positive trading session for ...

The stock's fall snapped a three-day winning streak.

President Donald Trump’s $3 billion funding freeze on Harvard University is starting to have an impact on the local real ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

A start-up that launched only 8 months ago has attracted the attention of Biogen, a major developer of neurological drugs.

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

Biogen ( NASDAQ: BIIB) and City Therapeutics signed a collaboration to develop novel RNA interference ( (RNAi)) therapies ...

Nearly two years in with Zurzuvae, Biogen tackles an ‘all of the above market’ to find patients and battle stigma in ...

Biogen and City Therapeutics have announced a partnership worth over $1bn to develop new RNAi therapies. The collaboration ...

Biogen Inc. is teaming up with a new startup launched by Alnylam Pharmaceuticals’ founding CEO John Maraganore.